Compare Stocks: OSTX, EBS, SION, and QTTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.80 -3.1%	$6.31	$4.36 ▼ $14.06	$359.94M	2.34	1.14 million shs	1.87 million shs
OSTX OS Therapies	$1.77 -3.3%	$1.63	$1.15 ▼ $2.25	$84.41M	-0.68	680,943 shs	908,323 shs
QTTB Q32 Bio	$10.54 -2.9%	$14.66	$1.72 ▼ $23.57	$323.30M	0.21	559,201 shs	972,323 shs
SION Sionna Therapeutics	$5.96 -17.0%	$22.51	$4.01 ▼ $54.97	$324.62M	0.89	1.30 million shs	3.68 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-3.10%	+8.74%	+38.74%	-14.89%	-12.66%
OSTX OS Therapies	-3.28%	+5.36%	+21.23%	-8.29%	-19.55%
QTTB Q32 Bio	-2.95%	-5.05%	-33.46%	-11.43%	+488.83%
SION Sionna Therapeutics	-16.99%	-24.08%	-4.64%	-84.02%	-73.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.80 -3.1%	$6.31	$4.36 ▼ $14.06	$359.94M	2.34	1.14 million shs	1.87 million shs
OSTX OS Therapies	$1.77 -3.3%	$1.63	$1.15 ▼ $2.25	$84.41M	-0.68	680,943 shs	908,323 shs
QTTB Q32 Bio	$10.54 -2.9%	$14.66	$1.72 ▼ $23.57	$323.30M	0.21	559,201 shs	972,323 shs
SION Sionna Therapeutics	$5.96 -17.0%	$22.51	$4.01 ▼ $54.97	$324.62M	0.89	1.30 million shs	3.68 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-3.10%	+8.74%	+38.74%	-14.89%	-12.66%
OSTX OS Therapies	-3.28%	+5.36%	+21.23%	-8.29%	-19.55%
QTTB Q32 Bio	-2.95%	-5.05%	-33.46%	-11.43%	+488.83%
SION Sionna Therapeutics	-16.99%	-24.08%	-4.64%	-84.02%	-73.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	2.17	Hold	$10.00	46.97% Upside
OSTX OS Therapies	2.75	Moderate Buy	$13.33	653.30% Upside
QTTB Q32 Bio	2.86	Moderate Buy	$31.00	194.12% Upside
SION Sionna Therapeutics	2.00	Hold	$42.33	610.29% Upside

Current Analyst Ratings Breakdown

Latest OSTX, EBS, SION, and QTTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	QTTB Q32 Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	SION Sionna Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$5.00 ➝ $6.00
9/9/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/7/2026	QTTB Q32 Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	QTTB Q32 Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$34.00
8/21/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/21/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/21/2026	EBS Emergent Biosolutions	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight
8/11/2026	EBS Emergent Biosolutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/10/2026	SION Sionna Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$742.90M	0.47	$3.54 per share	1.92	$9.95 per share	0.68
OSTX OS Therapies	N/A	N/A	N/A	N/A	($0.17) per share	N/A
QTTB Q32 Bio	$53.74M	5.84	$1.47 per share	7.16	$3.41 per share	3.09
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$6.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	9.19	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
OSTX OS Therapies	-$28.75M	-$0.79	N/A	3.00	N/A	N/A	N/A	-477.37%	N/A
QTTB Q32 Bio	$29.82M	$3.00	3.51	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A

Latest OSTX, EBS, SION, and QTTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	OSTX OS Therapies	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.70	5.42	2.95
OSTX OS Therapies	N/A	0.18	0.18
QTTB Q32 Bio	N/A	20.30	20.30
SION Sionna Therapeutics	N/A	20.05	20.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
OSTX OS Therapies	N/A
QTTB Q32 Bio	31.32%
SION Sionna Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	6.00%
OSTX OS Therapies	9.60%
QTTB Q32 Bio	34.46%
SION Sionna Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	900	51.27 million	48.20 million	Optionable
OSTX OS Therapies	5	46.13 million	41.70 million	N/A
QTTB Q32 Bio	22	29.77 million	19.51 million	N/A
SION Sionna Therapeutics	59	45.21 million	42.91 million	N/A

OSTX, EBS, SION, and QTTB Headlines

Recent News About These Companies

Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $42.22 Consensus Target Price from Analysts

September 18 at 3:44 AM | americanbankingnews.com

Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?

September 17 at 6:36 PM | finance.yahoo.com

A Biotech Company Had $268 Million in Cash. After a Failed Drug Trial, It Announced a 46 Percent Workforce Cut

September 17 at 1:35 PM | inc.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 17 at 10:00 AM | prnewswire.com

Sionna Therapeutics (NASDAQ:SION) Stock Price Expected to Rise, Wedbush Analyst Says

September 17 at 1:30 AM | americanbankingnews.com

Stifel Nicolaus Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)

September 16 at 5:32 PM | theglobeandmail.com

Waltham Biotech Sionna Cuts 46% of Staff After $2B Stock Collapse

September 16 at 12:32 PM | hoodline.comH

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

September 16 at 12:32 PM | finance.yahoo.com

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

September 16 at 12:31 PM | zacks.com

Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Price Target at $42.22

September 16 at 4:00 AM | defenseworld.netD

FDA clears first generic radioligand drug; Sionna turns to layoffs

September 15, 2026 | biopharmadive.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 15, 2026 | globenewswire.com

Sionna Advances New CF Combo To Phase 2a After SION-719 Setback, Cuts Workforce 46%; Stock Down

September 15, 2026 | rttnews.com

Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail

September 15, 2026 | fiercebiotech.comF

Sionna Therapeutics (NASDAQ:SION) Given New $6.00 Price Target at Wedbush

September 15, 2026 | marketbeat.com

Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript

September 15, 2026 | seekingalpha.com

Sionna Therapeutics (SION) Reiterated at Market Perform by Citizens Amid Ph2a Trial Issues

September 15, 2026 | streetinsider.com

Sionna Therapeutics to Cut 46% of Staff to Focus on Cystic Fibrosis Drug Development

September 14, 2026 | marketwatch.com

Sionna Therapeutics Restructures to Focus on Dual Combination

September 14, 2026 | tipranks.com

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

September 14, 2026 | globenewswire.com

Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of "Hold" by Brokerages

September 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OSTX, EBS, SION, and QTTB Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.80 -0.22 (-3.08%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$6.83 +0.02 (+0.37%)

As of 09/18/2026 08:00 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

OS Therapies NYSEAMERICAN:OSTX

$1.77 -0.06 (-3.28%)

Closing price 09/18/2026 04:10 PM Eastern

Extended Trading

$1.82 +0.05 (+2.82%)

As of 09/18/2026 07:41 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Q32 Bio NASDAQ:QTTB

$10.54 -0.32 (-2.95%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.89 +0.35 (+3.32%)

As of 09/18/2026 07:30 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Sionna Therapeutics NASDAQ:SION

$5.96 -1.22 (-16.99%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.03 +0.07 (+1.24%)

As of 09/18/2026 07:50 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSTX, EBS, SION, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSTX, EBS, SION, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSTX, EBS, SION, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OSTX, EBS, SION, and QTTB Company Descriptions

Emergent Biosolutions NYSE:EBS

OS Therapies NYSEAMERICAN:OSTX

Q32 Bio NASDAQ:QTTB

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSTX, EBS, SION, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSTX, EBS, SION, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSTX, EBS, SION, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OSTX, EBS, SION, and QTTB Company Descriptions

Emergent Biosolutions NYSE:EBS

OS Therapies NYSEAMERICAN:OSTX

Q32 Bio NASDAQ:QTTB

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools